Looking back on 2023, Merck & Co., Inc. and Roche Holding AG released less-than-impressive findings on their anti-TIGIT combinations in non-small cell lung cancer (NSCLC). The bright spot last year was Arcus Biosciences, Inc. and Gilead Sciences, Inc.’s anti-TIGIT/anti-programmed cell death ligand 1 (PD-L1) coformulation in gastric cancer, which showed greater efficacy than the standard of care for gastric cancers, particularly in high-PD-L1 expressers.
“Whilst it seems hope is not lost for the TIGIT drug class, Phase II data will not be sufficient to...